Physician profile
Rajesh V Putcha
NPI 1043296353
$209,850.85
in general payments reported to CMS, 2019-2025
26 companies · $127K in 2025
The $127K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $2,357 · 2021: $1,281 · 2022: $4,521 · 2023: $37K · 2024: $37K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Travel and Lodging: $16K · Consulting Fee: $8,055 · Food and Beverage: $6,852 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,985.66 |
| Travel and Lodging | $15,790.39 |
| Consulting Fee | $8,055.00 |
| Food and Beverage | $6,851.73 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $118,881.76 | 2022-2025 | Dupixent |
| Genzyme Corporation | $77,427.75 | 2022-2025 | |
| Medtronic, INC. | $4,739.78 | 2024-2025 | Endoflip, Gi Genius |
| Redhill Biopharma INC. | $3,088.49 | 2020-2021 | |
| Abbvie INC. | $2,577.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $635.52 | 2019-2025 | Entyvio |
| Pfizer INC. | $388.39 | 2023-2025 | |
| Janssen Biotech, INC. | $334.32 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.09 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $255.81 | 2024-2025 | Omvoh |
| Micro-Tech Endoscopy USA, INC. | $249.08 | 2019 | |
| Merck Sharp & Dohme LLC | $188.20 | 2021-2024 | Dificid, Zerbaxa |
| Amgen INC. | $143.89 | 2025 | Uplizna |
| Genentech USA, INC. | $123.99 | 2024 | Xolair |
| Ferring Pharmaceuticals INC. | $112.97 | 2019-2023 | Clenpiq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $80.14 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $68.43 | 2025 | Iqirvo |
| Celgene Corporation | $48.50 | 2022 | |
| Celltrion USA INC. | $47.72 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $31.52 | 2025 | Zenpep |
| Ardelyx, INC. | $30.84 | 2024-2025 | Ibsrela |
| Welch Allyn | $29.52 | 2021 | |
| Ironwood Pharmaceuticals, INC | $26.03 | 2019 | |
| Vivus LLC | $15.32 | 2025 | Pancreaze |
| Daiichi Sankyo INC. | $11.57 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Putcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.